Hi everyone, A generic SNOMED-CT concept has been created for the COVID-19 non-replicating vector vaccine group (the parent concept in which the AstraZeneca, COVISHIELD and Janssen vaccines fall under): - ConceptID: 29061000087103 - FSN: Vaccine product containing only non-replicating viral vector encoding protein of Severe acute respiratory syndrome coronavirus 2 (medicinal product) - PT: COVID-19 non-replicating vector vaccine - Syn: Vaccine product containing only non-replicating viral vector encoding protein of Severe acute respiratory syndrome coronavirus 2 | COVID-19 non-replicant vector vaccine The concept is in scope for the next CVC release. It has been created in the CA Edition and is in scope for the March CA Edition publication. It will also be sent to SI for candidate in the July 2021 INT release. The full RFC can be viewed here: https://informs.infoway-inforoute.ca/browse/SCT-11026?filter=-2 (note that you must register for an InfoCentral account and request access to Informs). Please don't hesitate to let me know if you have any questions. All the best, Taylor

Hi everyone, Thank you for participating in the CVC Monthly Meeting last week. Please find below a summary of updates and action items. COVID-19 Terminology SNOMED-CT Codes for COVISHIELD and Janssen COVID-19 vaccine products have been created: COVISHIELD - ConceptID: 28961000087105 - FSN: COVISHIELD 0.5 milliliter solution for injection Verity Pharmaceuticals Inc. (real clinical drug) - PT: COVID-19 COVISHIELD COVID-19 VP Syn: COVISHIELD 0.5 milliliter solution for injection Verity Pharmaceuticals Inc. Janssen (Johnson & Johnson) - ConceptID: 28951000087107 - FSN: JANSSEN COVID-19 0.5 milliliter suspension for injection Janssen Inc. (real clinical drug) - PT: COVID-19 JANSSEN COVID-19 Jan Syn: JANSSEN COVID-19 0.5 milliliter suspension for injection Janssen Inc. These concepts are in scope for the next CVC release and for the March CA Edition publication. Generic agent code: COVID-19 non-replicating viral vector - An RFC has been submitted to Canada Health Infoway to create a generic agent code for COVID-19 non-replicating viral vector vaccines (in which the AstraZeneca, COVISHIELD and Janssen products would fall under). - Link to RFC: https://informs.infoway-inforoute.ca/browse/SCT-11026?filter=-2 - Timeline: a code will be ready before the end of this week. Once it has been created, the CVC team will share with working group members via email and post in the Public Health Surveillance community forum. COVID-19 Pfizer Concept Modifications - Based on published product monograph and discussions with stakeholders, modifications to the COVID-19 Pfizer vaccine concept are as follows: - FSN: PFIZER-BIONTECH COVID-19 messenger ribonucleic acid 30 micrograms per 0.3 milliliter suspension for injection BioNTech Manufacturing GmbH - PT: COVID-19 PFIZER-BIONTECH COVID-19 mRNA PB - There were no issues raised by working group members with this change Governance Update - CVC team will share a draft Terms of Reference for the CVC Working Group and for a Clinical Advisory group within two weeks to solicit feedback prior to the next monthly meeting. Next CVC Release - CVC Version 1.1.8 is scheduled to be released on March 5th. Next CVC Meeting - The next CVC Working Group Monthly Meeting will take place on Tuesday, March 30th from 2-3pm EST. Please note that you must register in advance for this meeting (see details below). When: Mar 30, 2021 02:00 PM Eastern Time (US and Canada) Register in advance for this meeting: https://infoway-inforoute.zoom.us/meeting/register/tJUud-GqrzkiGtXX4o8L9CrP4bXRKwZO0JIe Please let us know if you have any questions, comments or feedback on the above. Best, Taylor

Hi everyone, The meeting agenda for this afternoon's CVC Monthly Meeting has been posted in the Public Health Surveillance community under Documents > Meeting Information > 2021. If you have not already registered and wish to attend the CVC Monthly meeting, please find registration information below. When: Feb 25, 2021 02:00 PM Eastern Time (US and Canada) Register in advance for this meeting: https://infoway-inforoute.zoom.us/meeting/register/tJIuc-Cgqz8tG9J6m9tuM6zKoN5KipKKKpkK

Hi everyone, A SNOMED CT code for the AstraZeneca vaccine has been created: ConceptID: 28761000087108 FSN: ASTRAZENECA COVID-19 0.5 milliliter solution for injection AstraZeneca Canada Inc. (real clinical drug) PT: COVID-19 ASTRAZENECA COVID-19 AZC Syn: ASTRAZENECA COVID-19 0.5 milliliter solution for injection AstraZeneca Canada Inc. This concept is in scope for the next CVC release, and in scope for the SNOMED March CA Edition publication. Update on Generic Concept for AstraZeneca and Janssen Vaccines To expedite the process of creating a code, the AstraZeneca COVID-19 concept has been created under the most generic COVID-19 term (28531000087107 |Vaccine product against disease caused by Severe acute respiratory syndrome coronavirus 2 (medicinal product)|). However, a more granular generic term for both the AstraZeneca and Janssen vaccines is recommended when it becomes available. Based on discussions with clinical subject matter experts (Dr. Sarah Wilson, Public Health Ontario & NACI Member; Dr. Monika Naus, Medical Director, Communicable Diseases & Immunization Service & Medical Head, Immunization Programs & Vaccine Preventable Diseases at the BCCDC) and sources gathered, the AZ and Janssen vaccines are considered "viral vector" vaccines, specifically, "non-replicating viral vector" vaccines. Both use adenoviruses as the viral vector, however, they do not use the same adenovirus vector. There has not been a perceived use case for creating such granular generic concepts at the level of the specific adenovirus. Therefore, we are proposing that the AZ and Janssen vaccines fall under a parent concept, "COVID-19 non-replicating viral vector" vaccine. For a schematic overview and scholarly references for this recommendation, please refer to the PHS Community documents section, under Meeting Information > 2021 > "CVC Working Group - Update on Generic Concept for AstraZeneca and Janssen COVID-19 Vaccines" We have confirmed with Linda Parisien that a generic concept for this does not exist, and have been informed that the SNOMED International community is currently working on developing terminology for this group of vaccines. New concepts for COVID-19 vaccines are anticipated to be available within the coming weeks from SNOMED International. This is also where the COVID-19 mRNA generic concept was drawn from in December. Once an appropriate term becomes available, the CVC will adopt this term as the parent of the AZ and Janssen vaccines, assuming that the concept aligns with the recommendations we have gathered from subject matter experts. Next CVC Release To include the AstraZeneca trade name code, we are proposing to push the next CVC release to next week with the following schedule: - Tuesday, February 16th: Prerelease sent to stakeholders for review - Thursday, February 18th: Deadline to provide feedback - Friday, February 19th: CVC Release Please let me know if you have any questions or concerns with the above.